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ABSTRACT 
Background: The role of different subtypes of tumour infiltrating lymphocytes (TILs) in breast 
ductal carcinoma in situ (DCIS) is still poorly defined. This study aimed to assess the 
prognostic significance of B and T lymphocytes and immune checkpoint proteins expression 
in DCIS. 
Methods: A well characterised DCIS cohort (n=700) with long-term follow-up comprising pure 
DCIS (n=508) and DCIS mixed with invasive carcinoma (IBC; n=192) were stained 
immunohistochemically for CD20, CD3, CD4, CD8, FOXP3, PD1 and PDL1. Copy number 
variation and TP53 mutation status were assessed in a subset of cases (n=58).  
Results: CD3+ lymphocytes were the predominant cell subtype in the pure DCIS cohort, while 
FOXP3 showed the lowest levels. PDL1 expression was mainly seen in the stromal TILs. Higher 
abundance of TILs subtypes was associated with higher tumour grade, hormone receptor 
negativity and HER2 positivity. Mutant TP53 variants were associated with higher levels of 
stromal CD3+, CD4+ and FOXP3+ cells. DCIS coexisting with invasive carcinoma harboured 
denser stromal infiltrates of all immune cells and checkpoint proteins apart from CD4+ cells. 
Stromal PD1 was the most differentially expressed protein between DCIS and invasive 
carcinoma (Z=5.8, p<0.0001). Dense TILs, stromal FOXP3 and PDL1 were poor prognostic 
factors for DCIS recurrence, while dense TILs was independently associated with poor 
outcome for all recurrences (HR=7.0; p=0.024), and invasive recurrence (HR=2.1; p=0.029).  
Conclusion: Immunosuppressive proteins are potential markers for high risk DCIS and disease 
progression. Different stromal and intratumoural lymphocyte composition between pure 
DCIS, DCIS associated with IBC and invasive carcinoma play a potential role in their 
prognostic significance and related to the underlying genomic instability. Assessment of 
overall TILs provides a promising tool for evaluation of the DCIS immune microenvironment.  
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Background 
The incidence of breast ductal carcinoma in situ (DCIS) increased dramatically after the 
introduction of mammographic screening and accounts up to 25% of the screen detected 
breast cancers in the UK with similar rates in the US 1,2. However, management of DCIS 
remains as a clinical challenge with a considerable proportion of patients are either over- or 
under-treated due to the lack of a robust prognostic assessment model to stratify patients’ 
risk. Current management decisions rely on conventional clinicopathological parameters as 
the clinical utility of available gene expression assays and molecular prognostic biomarkers 
remain to be demonstrated. It is hence important to identify other robust markers for DCIS 
for behaviour predilection to decide a personalised treatment approach.  
Although the role of tumour microenvironment in disease behaviour is undeniable, 
incorporation of the microenviromental factors with the clinicopathological and/or molecular 
signature for DCIS risk assessment is still limited. The tumour immune microenvironment 
undergoes several changes during carcinogenesis 3. The triggering of an immune response in 
the form of infiltration of lymphocytes and other inflammatory mediators is a phenomenon 
known as “cancer immuno-editing” 4. It is known that subtype, density and location of tumour 
infiltrating lymphocytes (TILs) play a role in cancer prognosis. Infiltration of T lymphocytes 
extends an anti-tumour response through the CD8+ cytotoxic T lymphocytes while an 
immunosuppressive response occurs through CD4+ FOXP3+ regulatory T cells (Tregs) 5,6. 
Similarly, CD20+ B lymphocytes are associated with a humoral anti-tumour response 7. The 
role of TILs in invasive breast cancer (IBC) is well validated, with a high TILs density 
associated with better response to adjuvant or neoadjuvant therapy and favourable outcome 
especially in triple negative (TNBC) and HER2+ subtypes 8-13. However, there are conflicting 
data for the role of TILs in DCIS prognosis with some studies claiming an unfavourable role 
14 while others did not find association with the outcome 15,16. 
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An important component of immuno-editing is the development of an immunosuppressive 
microenvironment mediated through the activation of the immune checkpoint pathway. The 
programmed cell death 1 (PD1) protein, a member of the B7/CD28 family of co-stimulatory 
receptors present mainly on T cells, sends inhibitory signals to T cells to suppress the anti-
tumour response 4,17. PD1 functions mainly through its ligand PDL1, which is expressed on a 
variety of immune cells such as antigen presenting cells and activated T and B lymphocytes 
and tumour cells 18,19. Revolutionary results have been achieved from clinical trials involving 
monoclonal antibodies that target PD1 and block the PD1/PDL1 pathway in patients with non-
small cell lung cancer, melanoma and renal cancer 20.  
In a previous study we have demonstrated the prognostic value of TILs, as assessed on H&E 
stained slides, in DCIS 14. Here we hypothesised that various immune cell subpopulations and 
the immune checkpoint proteins play roles in DCIS behaviour and this can be related to the 
underlying molecular prolife. In this study, we evaluated the expression and the prognostic 
significance of T and B lymphocytes and immune checkpoint proteins PD1 and PDL1 in a large 
well characterised DCIS cohort with long-term follow up. We also investigated the relationship 
between genomic copy number alteration and TP53 variants (as measures of genomic 
instability) with immune cell infiltration in a subset of cases. 
MATERIALS AND METHODS 
Study Cohort 
This study was conducted on a well characterised annotated large DCIS cohort, comprising 
primary pure DCIS cases and DCIS associated with invasive tumour (DCIS-mixed) diagnosed 
at Nottingham City Hospital, Nottingham, UK, between 1990 to 2012 as described 21. The 
clinicopathological characteristics of the study cohort are summarised in Supplementary Table 
1. The patients’ demographic data, histopathological parameters, overall TILs density, DCIS 
management including post-operative radiotherapy (RT) and development of local recurrence 
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along with patient outcome was available. Tumour grade was classified according to the three-
tier system; low, intermediate and high grades 22. Local recurrence free interval (LRFI) was 
defined as the time interval (in months) between 6 months after the primary DCIS surgery 
and occurrence of ipsilateral local recurrence either as DCIS or IBC. Recurrence was 
considered when it occurred in the same quadrant and showed a similar nuclear grade or 
higher than the primary tumour. In this study, cases with new lesions in other quadrants, or 
with lower nuclear grade and tumours developing in the contralateral breast were not counted 
as a recurrence and were censored at time of development of the new event. All recurrence 
events were checked 3 times by 3 researchers with pathology experience. Moreover, they 
were histologically reviewed to ensure that the morphology matches that stated in the original 
histology. We did our best to differentiate true recurrences from new primary tumors with 
acknowledgement of the limitations of our ability to accurately make such a distinction. We 
are interested in the behaviour of DCIS under investigation rather than the risk of other events 
that happened following the primary diagnosis of DCIS, either new primary ipsilateral or 
contralateral events. We have not included these events in our analysis to avoid the 
confounding effects of these tumours, which may have different biological characteristics 
features.       
Data on Oestrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth 
Factor Receptor 2 (HER2), Ki-67, TP53, CK5/6, and HIF-1α were available to this cohort as 
previously described. Briefly, ER and PR positivity were both defined as ≥1% nuclear tumour 
staining 23. Immunoreactivity of was scored using HercepTest guidelines. Chromogenic in situ 
Hybridisation (CISH) was used to assess HER2 gene amplification in cases with 2+ score using 
the HER2 CISH pharmDx™ kit (Dako) 24. Proliferation index was evaluated through Ki-67 
antibody immunohistochemical (IHC) staining and defined as high when ≥14% of cells showed 
nuclear positivity 25. The molecular subtypes were classified as: Luminal A (ER+ and/or PR+, 
HER2- and Ki67 low), Luminal B (ER+ and/or PR+, HER2- and Ki67 high or ER+ and HER2+), 
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HER2 enriched (HER2+ and ER-) and Triple Negative (ER-, PR- and HER2-). TP53 and CK5/6 
proteins were assessed immunohistochemically, and the percentage of positive nuclear and 
membranous expression were scored, respectively. More than 1% HIF-1α nuclear 
immunoreactivity was considered positive 26,27. High TIL density was considered where the 
average number lymphocytes/duct was 20 or more 14.  
Immunohistochemistry of immune cell markers and checkpoint proteins  
Tissue microarrays (TMAs) were prepared from both cohorts using a TMA Grand Master 2.4-
UG-EN machine (3D Histech) with 1mm punch sets. The TMA was prepared from all 
representative areas of heterogeneous morphology and grade, when present. Apart from the 
TMAs, 30 full face sections were also assessed to reveal the infiltration pattern of various TILs 
subtypes and immune checkpoint proteins.  
Immunohistochemical staining (IHC) was performed on TMA sections using a Novocastra 
Novolink TM Polymer Detection Systems Kit (Code: RE7280-K, Leica, Biosystems, UK). 
Primary antibody specific for CD20 (mouse monoclonal, DAKO Clone L26/M0755), CD3 (rabbit 
monoclonal antibody [SP7], Abcam (ab16669)), CD8 (mouse monoclonal, DAKO Clone 
C8/144B), CD4 (rabbit monoclonal antibody [EPR6855], Abcam (ab133616)), FOXP3 (mouse 
monoclonal [236A/E7), Abcam (ab20034)), PD1 (Mouse monoclonal [EH33] Cell signalling 
(43248S)), PDL1 (Rabbit monoclonal antibody [E1L3N] Cell signalling (13684S)) were used 
to characterise TILs and immune checkpoint proteins. Supplementary Table 2 summarises 
the details of the antibodies used for IHC staining. Sections from normal tonsil were used as 
a positive control while a negative control was generated by omitting the primary antibodies. 
Immunoscoring 
Stained slides were digitally scanned using a Nannozoomer (Hamamatsu Photonics), at 20X 
magnification high resolution images and viewed using the Aperio ImageScope Viewer 
software version 12.3.3 (developed by Leica Biosystems Imaging). All cases were scored 
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visually using the digitised images for stromal expression of TILs as previous described 14, 
and for intratumour TILs. Briefly, the average number of lymphocytes touching DCIS 
basement membrane or away from it by one lymphocyte cell thickness was counted. In 
addition, the average number of intratumour TILs per duct was counted for CD20, CD3, CD4, 
CD8, FOXP3 and PD1. PDL1 expression in tumour epithelial cells was scored as percent of 
cells showing membranous and/or cytoplasmic staining, where cases with >1% positive cells 
were considered positive 15. The pure DCIS and the in-situ component of mixed cases which 
clearly defined a demarcated tumour edge were assessed, separately. Average score was 
used as a final score for cases with multiple cores. All cases were scored independently by 
two observers (A Abidi and M Toss) blinded to patient histopathological data and clinical 
outcome. The average score was considered in discrepant cases between the two observers.  
DNA Extraction, targeted sequencing library preparation, enrichment, and 
sequencing  
Sections from formalin-fixed paraffin-embedded (FFPE) blocks from a subset of DCIS cases 
(n=58) were reviewed by two pathologists to select representative sections. The cases were 
randomly selected based on tissue block availability and adequacy of tumour tissue for DNA 
extraction. Tumour epithelial cells were needle-microdissected from 10 µm sections (8 – 20 
slides) after haematoxylin staining and DNA was isolated using the AllPrep DNA/RNA FFPE kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Targeted sequencing of 
tumour DNA was performed using an Agilent SureSelect XT Custom Panel (Agilent, Santa 
Clara, CA, USA) which targeted breast cancer specific genes including TP53. Library 
preparation was performed from at least 80 ng of tumour DNA using the KAPA Hyper system 
(Agilent). For samples with lower DNA yields available (≤ 10ng), library preparation was 
performed with the NEBNext® Ultra™ II DNA Library Prep Kit (New England BioLabs® Inc, 
Ipswich, MA, USA) and used for low-coverage whole-genome sequencing (LC-WGS) as 
described previously 28. Illumina Nextseq500 (paired-end 75 bp reads) was used to run 
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pooled, normalised, indexed libraries according to Illumina protocols. Average sequencing 
depth was 400X (SureSelect) and 1.3X (LC-WGS). 
Copy number and variant data analysis 
Data was processed by an in-house bioinformatics pipeline at the Peter MacCallum Cancer 
Centre (Melbourne) to detect and filter for high confidence somatic variants. Paired‐end 
sequence reads were aligned to the g1 k v37 hg19 reference genome using BWA. Optical 
duplicate reads were removed using Picard and the Genome Analysis Tool Kit (GATK) was 
used to perform local realignment around indels and base quality score recalibration in 
accordance with the recommended best practice workflow 29. Single nucleotide polymorphism 
(SNP) and indel variants were called using GATK Unified Genotyper, Platypus 30, and Varscan 
2 31. Called variants were annotated using the Ensembl Variant Effect Predictor 32. Somatic 
mutations were identified by removing previously available germline variant data for 
hereditary breast and ovarian cancer panel genes and by applying the following filters; 
canonical transcript; bidirectional read; quality ≥100; variants identified by at least two 
variant callers; minor allele frequency (MAF) present at ≤0.0001 in ExAc (Version 0.3.1, 
excluding TCGA data) 33, GnomAD (Version 2.0), EVS (Version ESP6500SI‐V2‐SSA137) 
[Exome Variant Server, available http://evs.gs.washington.edu/EVS/], and 1000 Genomes 34 
databases. Genomics regions identified by Scheinin et al 35 were removed from analysis as 
described previously 28. 
Copy number profiles were obtained using the SureSelect panel off-target reads with 
CopywriteR 36 and Control-FREEC for LC-WGS reads 37. A lymphocyte DNA control run 
(NA12878, Coriell Institute) in the same sequencing batch was used for baseline 
normalisation. Data were then imported to NEXUS Copy Number™ (software v9.0; 
BioDiscovery Inc, El Segundo, CA, USA), segmented using a FASST2 segmentation algorithm 
and visualised using a circular binary segmentation algorithm to determine gains and losses 
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as described 38. Fraction of the genome altered (FGA) was calculated as the percentage of 
base pairs with copy number gain or loss. Number of telomeric allelic imbalances (NTAI) was 
calculated as the count of telomeres (excluding chromosome Y) with a gain or loss 15. Twenty 
cases showed deleterious/missense TP53 variants annotated as described above. 
Statistical Analysis 
All statistical tests were conducted on IBM SPSS software (version 24.0, Chicago, IL, USA) 
for Windows. For the dichotomisation of the immune cells and checkpoint protein densities, 
median values were used as cut off points.  
Spearman’s Rho test was used to correlate between the expression of different immune cells 
with each other, overall TILs and with the proliferation marker (Ki67), TP53 and HIF-1α. Chi 
square test was used to determine the association between different markers densities with 
other clinicopathological parameters. Expression of PDL1 within the tumour cells was not 
included in the analysis as the percentage of positive cases was very low (2% only). Mann-
Whitney U test and Kruskal-Wallis test were used to compare between TILs densities and 
FGA, NTAI and TP53 variants. Differential expression of various study markers between pure 
DCIS and DCIS coexisting with IBC was analysed using the continuous score data and the 
Mann-Whitney U test. The association with LRFI was assessed in univariate analysis using 
Kaplan Meier curves and Log Rank Test. Cox regression was carried out for multivariate 
analysis to adjust for confounding by conventional prognostic factors. Survival analyses were 
confined to patients treated with breast conserving surgery (BCS) with or without 
radiotherapy as it was the highest group showing ipsilateral recurrence (>95% of recurrences) 
and the smaller number of events in patients treated with mastectomy. For each test 
conducted, a two-tailed p-value of <0.05 was considered statistically significant. 
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RESULTS 
Patterns of expression and distribution of various inflammatory cells and immune 
checkpoints  
The assessment of the full-face sections revealed that TILs infiltration was comparable to the 
TMA sections thus justifying the representability of the TMA sections for immunoscoring both 
in the stromal and intratumoural compartments. Uninformative cores (lost, folded tissue or 
cores containing <15% tumour cells and/or stroma) were excluded from scoring. 
Supplementary Table 3 summarises the distribution of various types of lymphocytes as well 
as PD1 and PDL1 expression either in the stroma or intratumourally. The predominant 
lymphocytes in DCIS were CD3+ cells either intratumourally (median 1 cell/duct, range 0-50) 
or in the stroma (median 3 cells/duct, range 0-100) whereas CD4+ cells were the most 
frequent subtype of T cells (range 0-60 in the stroma and 0-25 in the intratumoural 
compartment). Stromal FOXP3+ lymphocytes were the least frequent (median 0 cells/duct, 
range 0-25) while PD1+ cells were the lowest type intratumourally (median 0 cells/duct, range 
0-15). Only 2% of pure DCIS cases showed positive expression for PDL1 within tumour cells. 
Figure 1 and Supplementary Figure 1 show examples of dense TIL infiltrates in H&E and IHC 
stained sections with various markers demonstrating the distribution of immune cells and 
immune checkpoint protein in pure DCIS.  
Stromal CD3+, CD8+, CD4+, PDL1+ and PD1+ lymphocytes showed the highest correlation 
with overall TILs (all r>0.4, p<0.0001). The strongest correlation between various 
lymphocytes was observed with CD3+ and CD4+ lymphocytes (r=0.96, p<0.0001), followed 
by CD4+ and CD8+ cells (r=0.94, p<0.0001). Figure 2A shows a correlation matrix that 
summarises the associations between overall TILs, various immune cell subtypes, PD1, PDL1, 
hormonal receptors, Ki67, HIF-1α, CK5/6 and p53 protein.  
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Moreover, DCIS mixed with synchronous IBC harboured more dense stromal TILs, PD1, PDL1 
and various subpopulation of lymphocytes within the stroma than pure DCIS, with the highest 
difference observed with stromal PD1+ (Z=5.8, p<0.0001) followed by stromal CD8+ (Z=5.5, 
p<0.0001). Only stromal CD4+ cells did not show a significant statistical difference between 
both groups. In the context of intratumoural immune cells, there was no difference in immune 
cells infiltrates between pure DCIS and DCIS mixed apart from intratumoural CD20 which was 
more prevalent in pure DCIS (Z=2.7, p=0.007) and PD1 which was more dense in DCIS 
associated with IBC (Z=2.2, p=0.025). Figure 2B and Supplementary Figure 2 demonstrate 
the differences in various immune cell markers between both groups.  
Association of immune cells subpopulations and immune checkpoint proteins with 
other clinicopathological parameters in pure DCIS cohort 
Higher expression of the majority of markers, either stromal or within the intratumoural 
comportment, was associated with hormonal receptor negativity. The exceptions were 
intratumoural CD20+ cells, which were associated with ER and PR positivity, and 
intratumoural CD3+, CD8+ and CD4+, which showed no association with ER or PR. High 
expression of all markers within the stroma, and intratumoural expression of PD1 and FOXP3, 
was associated with higher nuclear grade, HER2 positivity, and higher expression of HIF-1α. 
DCIS with smaller size and lower expression of HIF-1α showed higher expression of 
intratumoural CD20+ lymphocytes. It was also observed that dense infiltration of PD1, CD3, 
CD8, CD20 and FOXP3 in the stromal region was significantly associated with the presence of 
comedo-type necrosis. Supplementary Table 4 (a-d) shows the correlation between various 
immune cells/checkpoint markers and the clinicopathological parameters in the pure DCIS 
cohort. 
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Copy number variation and TP53 mutations 
Higher FGA was associated with higher tumour grade (p=0.002), presence of comedo type 
necrosis (p=0.0003), ER negativity (p=0.009), HER2 positivity (p=0.0003) and presence of 
at least one deleterious/missense TP53 variant (p<0.0001); (Supplementary Figure 3). 
Additionally, a higher NTAI was associated with high grade DCIS (p=0.008), presence of 
comedo type necrosis (p=0.006), HER2 positivity (p=0.03), and with presence of 
deleterious/missense TP53 variants (p=0.002). The median FGA in pure DCIS with dense TIL 
was 26% compared to 12% in cases with sparse TILs, however the difference was not 
statistically significant (p=0.08, Figure 3). Similar results were observed with stromal CD3 
whereas median FGA in pure DCIS with dense CD3+ cells was 26% compared to 10% in cases 
with sparse CD3+ cells (p=0.07, Figure 3). No association between NTAI and TILs density nor 
immune cell/checkpoint proteins was observed. However, tumours carrying somatic 
deleterious/missense TP53 variants showed higher counts of stromal CD3+ (p=0.031), CD4+ 
(p=0.04), and FOXP3+ (p=0.02); (Figure 3).  
Outcome Analysis 
High expression of stromal FOXP3+ and stromal PDL1+ were the sole markers associated 
with all recurrences in DCIS patients treated with BCS (HR=2.1, 95%CI=1.1-3.7, p=0.025 
and HR=4.4, 95%CI=2.4-8.1, p<0.0001, respectively); Figure 4A and 4B. When analysis was 
restricted to invasive recurrences, only stromal PDL1 was associated with shorter LRFI 
(HR=2.4, 95%CI=1.1-5.3, p=0.032), Figure 4C. As previous reported 14; overall TILs density 
was associated with shorter LRFI either for all recurrences (HR=2.9, 95%CI=1.7-5.0, 
p=0.0001 or invasive recurrences (HR=2.1, 95%CI=1.1-4.3, p=0.04). No significant 
associations with recurrence were observed for the intratumoural infiltration of any immune 
cell marker with recurrence (Table 1). Outcome analysis in context of various intrinsic 
molecular subtypes revealed that high expression of stromal FOXP3 was associated with 
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shorter LRFI in luminal A subtype (HR=2.9, 95%CI=1.1-8.1, p=0.032) while higher PDL1 
expression in stromal TILs was associated with shorter LRFI in luminal A (HR=7.1, 
95%CI=2.9-12.2, p<0.0001) and showing a trend of poor prognosis in luminal B (HR=3.2, 
95%CI=0.9-8.9, p=0.067) and HER2 enriched (HR=1.8, 95%CI=0.5-7.5, p=0.080) 
subtypes. Other markers did not show association with outcome in different molecular classes.  
In multivariate survival analysis, higher expression of stromal PDL1 was associated with 
shorter LRFI for all DCIS recurrences (but not for invasive recurrences only) independent of 
other parameters of DCIS aggressiveness including age at diagnosis, DCIS size, nuclear 
grade, presence of comedo-type necrosis and margin status (HR= 2.9, 95% CI=1.4-6.1, p= 
0.005). Interestingly, dense TILs was independently associated with DCIS recurrence either 
when included in a model comprising FOXP3+ and PDL1+ cells, or in a model where all 
immune cell markers associated with DCIS recurrence were incorporated with other DCIS 
clinicopathological parameters. A statistically significant result was obtained for all 
recurrences or when the analysis was confined to invasive recurrence only. Table 2 A and B 
summarise the various multivariate models analysed. 
Moreover, high TILs density and high stromal PDL1+ expression could categorise high risk 
DCIS defined as high grade DCIS and larger than >15mm in size into two distinct groups with 
different outcome; whereas high TILs and stromal PDL1+ cells were associated with shorter 
LRFI in these patients (HR=3.2, 95%CI=1.1-9.5, p=0.039, and HR=2.5, 95%CI=1.1-6.3, 
p=0.044, respectively) (Supplementary Figure 4).          
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DISCUSSION 
The importance of the tumour microenvironment dynamics during the neoplastic 
transformation of breast epithelial tissue is increasingly being recognised and is considered 
as a hallmark of cancer 3,39,40. However, the effect of infiltrating lymphocytes in various 
malignancies including DCIS is controversial 14-16,41-43 and the role of PD1 and PDL1 proteins 
in DCIS remains to be defined. Through this study, we aimed to characterise TIL subtypes 
and their potential prognostic role in DCIS. The dominance of CD3+ cells, including CD4+ and 
CD8+ subsets, indicates the immunologically active state of these early tumours, which could 
suggest an active chemokine secretion recruitment mechanism 44. Apart from cell-mediated 
immunity, an active humoral immune response is also indicated with the high expression of 
CD20+ cells. This result suggests that maturation of B lymphocytes may occur at an early 
stage of tumour development 45. In comparison to pure DCIS, DCIS with synchronous IBC 
had notably increased levels of CD8+, CD20+, FOXP3+, PD1+ and PDL1+ cells. Since FOXP3 
is the single most accurate marker of regulatory T cells (Tregs) 46, the high expression of 
FOXP3+ cells in a proportion of DCIS in addition to high expression of PDL1 suggests an 
immunosuppressive environment being created simultaneously in early tumour development, 
in concordance with previous studies 47,48,49. A recent review by Chen et al summarised 
findings from previous work that support our study findings, such as high grade DCIS 
harbouring more TILs than low grade lesions and being associated with underlying genetic 
alterations 50. 
We observed a significantly decreased recurrence-free survival in patients with a higher 
stromal infiltration of FOXP3. This suppressive environment appears to be particularly 
important for differentiating outcome in luminal A tumours, in which both FOXP3+ and PDL1+ 
were associated with poor outcome. FOXP3 was also described as an independent negative 
prognostic marker in IBC 51. Higher infiltration of FOXP3+ cells also predicts poor overall 
survival in ovarian carcinoma where release of the chemokine CCL22 in the tumour 
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microenvironment by tumour associated macrophages facilitates the recruitment of FOXP3+ 
Tregs and hence, the suppression of cytotoxic T cells 52. Another mechanism by which FOXP3 
aids in tumour recurrence could be by binding to the upstream region of transcription start 
site of chemokines such as CCR7 and CXCR4.  
The crucial role of the PD1/PDL1 pathway in the attenuation of T cell mediated immunity is 
well established 53. We observed that high expression of stromal PDL1, but not PD1, was 
associated with a shorter recurrence free interval. High expression of PDL1 is associated with 
a poorer outcome in pancreatic cancer, renal cell carcinoma and breast cancer 54-56. Similarly, 
high expression of PD1 is associated with poorer outcome in renal cell carcinoma and breast 
cancer 57,58. This association can be explained by the attenuation of the cytotoxic function of 
T lymphocytes in the presence of active PD1/PDL1 interactions thus aiding the tumour in its 
escape mechanisms 17,59. Another mechanism that might be at play is the upregulation of the 
PI3K pathway due to loss of PTEN or mutation of PIK3CA which ultimately leads to 
upregulation of PDL1 60. However, we saw no association of PIK3CA mutations with PDL1 
positivity.  
Despite the associations of an immunosuppressive microenvironment in DCIS with 
recurrence, in our multivariate analysis, overall TIL density was the strongest independent 
predictor for invasive recurrence. Since we did not find any significant associations of dense 
intratumoural infiltration of any immune cell with recurrence, we consider that assessment of 
stromal infiltration of different subtypes of TILs is a better method of TILs evaluation for 
outcome analysis in DCIS 14. It is similarly recommended to assess stromal TILs in IBC, but 
in IBC TILs are strongly associated with better outcome, particularly in TNBC 38. The 
contradictory association of TILs as a good prognostic marker in IBC and as a poor prognostic 
marker in DCIS could support a hypothesis that direct contact between invasive tumour cells 
and immune cells leads to destruction of tumour cells and hence better prognosis, while in 
DCIS, a dense inflammatory reaction could provide a way for destruction of the surrounding 
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myoepithelial layer 61 and basement membrane. This facilitation of tumour cell infiltration to 
the surrounding stroma 62 would be enhanced by the immunosuppressive proteins produced 
by the tumour cells to escape destruction by host immunity and guarantee maintenance of 
the invasive tumour cells 49.  
An alternative (and not necessarily exclusive) explanation could be that a heightened immune 
response in DCIS and its association with poor prognosis reflects an underlying aggressive 
breast tumour biology. Our findings regarding the significant association of the stromal 
immune markers with higher grade, HER2 positivity and hormone receptor negativity has 
been reported previously in DCIS 63 and IBC 38. The ability to recruit more inflammatory cells 
through production of neoantigens and chemokines, as well as their ability to modulate the 
immunosuppressive microenvironment to evade the host immune response, combine to 
develop the immune resistance shown by these tumours and lead to still further aggressive 
behaviour 64. ER negative DCIS are more proliferative and genomically unstable, hence 
stimulate a stronger attack from the immune cells. The association of dense infiltration in 
HER2+ tumours and TNBC can be best interpreted as a pro-tumourigenic function of TILs 
especially due to higher infiltration of Tregs 10,63. Our findings regarding the association of 
PD1 and PDL1 in TILs with higher tumour grade, were supported by the findings of Muenst et 
al. 58. This association with higher grade emphasises the role of PD1/PDL1 pathway adopted 
by DCIS to evade anti-tumour immunity and spread aggressively. Higher expression of PDL1 
in TNBC has also been reported in other studies 60,65. The association of more proliferative 
tumours such as HER2 enriched, TNBC and basal like tumours, with high expression of PDL1 
could be due to the increased immunogenicity of these tumours and increased presence of 
neoantigens.  
All solid tumours elicit an inflammatory response that is critical for the recruitment of immune 
cells, tumour cell proliferation, survival, and angiogenesis. Tumours initiate these responses 
through several mechanisms including hypoxia and derived factors 66. Hypoxia was reported 
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to shape the immunosuppressive microenvironment of the tumour 67. The positive correlation 
between HIF1a and FOXP3 in our study supports such a hypothesis and shows the crosstalk 
between tumour microenviroment components in DCIS progression. This finding is supported 
other studies that showed tight interaction between hypoxia and the tumour inflammatory 
process 66,68.  
DCIS harbouring dense inflammatory cells was reported to have more copy number alteration 
15 and higher Oncotype DX score 69 than those with low TILs density, which reflect the 
underlying biological association between TILs density and DCIS behaviour.  As expected, in 
our study high risk DCIS (high grade, comedo type necrosis, hormonal receptor negativity 
and HER2 positivity) showed a higher degree of genomic instability represented by an 
increased burden chromosomal gains and losses and the presence of deleterious/missense 
TP53 mutations 70. In general, genomic instability leading to high risk DCIS lesions might 
promote T cell activation (CD3 and CD4) and recruitment of regulatory T cells (FOXP3) as 
suggested by our data. These findings are supported by Hendry et al, who concluded that 
tumour immune-editing and evasion of the immune system could be a key step in progression 
from DCIS into IBC 15. Our data lacked sufficient numbers of cases analysed for mutation and 
CNVs to evaluate the interaction of these events with the immune context in terms of patient 
outcome. 
Our findings could refine high risk DCIS into two distinct groups based on TILs density and 
stromal PDL1 expression, where high risk cases with dense TILs or higher stromal PDL1+ cells 
behaved more aggressively and had higher recurrence rate than high risk DCIS with lower 
TILs or stromal PDL1+ cells. This observation reflects the role of immune microenviroment in 
DCIS risk stratification and management guidance. Implementation of TILs evaluation in 
clinical practice could avoid further management, i.e. unnecessary postoperative radiotherapy 
in a subgroup of patients.        
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In our study, evaluation of TILs in the routine H&E sections was the only inflammatory related 
tool that showed independent association with DCIS recurrence, especially with invasive 
recurrence. Taken together, assessment of TILs in H&E sections could provide a robust 
prognostic data with no need for further specific immune cell markers assessment.  
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Conclusion 
This study highlights the importance of the immune microenvironment playing a role in DCIS 
behaviour. Subsets of TILs, immune checkpoint proteins and their distribution should be 
carefully analysed for patient risk assessment. Since patient risk stratification has been 
difficult due to conflicting evidence regarding TILs affecting DCIS prognosis, this study 
provides a more uniform inference with the higher infiltration of FOXP3+ and PDL1 immune 
cells being associated with poor outcome. Further mechanistic studies to clarify the crosstalk 
between DCIS tumour cells and the immune microenvironment are warranted. 
Limitation of the study 
This study was conducted on TMA sections which may underestimate TILs infiltration although 
we did compare the distribution between TMA cores and full-face sections which showed 
comparability. In addition, due to the small number of recurrence events in patients treated 
with RT or when the cohort was split by molecular class or risk groups (high vs. low risk 
DCIS), further studies of TILs in context of these limitations are recommended. Also, the role 
of hormonal therapy is overlooked here as none of the study patients received such therapy.  
Data from genomic assessment was only available for a small subset of tumours limiting 
statistical power and the capability to conduct sub-group analysis (e.g. stratification by 
receptor status or grade), which might have weakened associations between TIL subtypes 
and genetic features.  
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Figure legends 
 
Figure 1: Photomicrograph for immune cells and checkpoint proteins in DCIS; A) Dense 
Overall TILs infiltration in H&E stained sections (20x). Dense stromal and intratumoral 
infiltration of various immune cell markers, B) CD3, C) CD4, D) CD8, E) CD20, F) FOXP3, G) 
PD1 and H) PDL1. Expression of PDL1 within the tumor epithelial cells is shown in (I). Green 
arrows highlight the intratumoral lymphocytes. Inset: higher magnification (40x) showing 
stromal FOXP3 positive cells. 
 
Figure 2: A) Correlation Matrix showing the correlation between TILs subtypes, overall TILs, 
and other associated biomarkers. (s; stromal, i; intratumoral). Blue colour refers to positive 
correlation, while the red colour reflects negative correlations. The intensity of the colour 
propionate to the correlation coefficient. B) Tornado (Butterfly) plot showing the differential 
expression level of various lymphocytes between pure DCIS and DCIS mixed with 
synchronous invasive breast cancer (IBC). 
 
Figure 3: Violin plots showing the association between TP53 variants and (A) stromal CD3+ 
cells, (B) stromal CD4+ cells, (C) stromal FOXP3+ cells and (D) stromal PDL1+ TILs. The 
lower figures show the association between fraction of genome altered and (E) overall TILs 
density and (F) stromal CD3+ cells. The central red dots represent the mean, boxes represent 
the interquartile range, central line represent the median and whiskers shows the 95% 
confidence interval.  
 
Figure 4: Kaplan Meier Curves showing; Higher stromal FOXP3+ cells was associated with 
poor outcome for all DCIS recurrences (A), Dense stromal PDL1 expression was associated 
with shorter local recurrence free interval (LRFI) either for all recurrences (B), or invasive 
recurrences (C). All analyses were carried out on patients treated with breast conserving 
surgery with or without radiotherapy.    
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Table 1: Univariate survival analysis between overall TILs and various immune cell markers with the local 
recurrence free interval in DCIS patients treated with breast conserving surgery  
Marker 
All recurrences Invasive recurrences 
Hazard 
ratio 
95% Confidence interval  p-value Hazard 
ratio 
95% Confidence interval  p-value 
Lower Upper Lower Upper 
Overall TILs 2.9 1.7 5.0 0.0001 2.1 1.1 4.3 0.040 
sCD20 0.9 0.5 1.7 0.793 0.9 0.4 1.9 0.770 
sCD3 1.1 0.6 1.9 0.877 0.8 0.4 1.7 0.563 
sCD8 0.9 0.5 1.8 0.992 0.5 0.2 1.2 0.109 
sCD4 1.5 0.9 2.8 0.150 1.2 0.5 2.5 0.708 
sFOXP3 2.1 1.1 3.7 0.025 1.1 0.4 2.6 0.895 
sPD1 1.3 0.7 2.3 0.412 0.7 0.3 1.6 0.347 
sPDL-1 4.4 2.4 8.1 <0.0001 2.4 1.1 5.3 0.032 
iCD20 1.2 0.7 2.2 0.520 1.1 0.5 2.3 0.937 
iCD3 1.2 0.7 2.2 0.522 0.9 0.5 2.1 0.979 
iCD8 1.1 0.6 1.9 0.839 0.7 0.3 1.7 0.529 
iCD4 1.2 0.7 2.1 0.572 1.1 0.5 2.2 0.985 
iFOXP3 1.6 0.8 3.3 0.180 0.7 0.2 2.5 0.617 
iPD1 0.9 0.4 2.1 0.766 0.7 0.2 2.5 0.652 
 s: Stromal, i: Intratumoral. 
Significant p values are in bold 
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Table 2: Multivariate survival analysis (Cox regression model) of variables (with and without immune cell 
markers) predicting outcome in terms of ipsilateral local all recurrences (A) and invasive recurrences (B) 
in patients treated by breast conserving surgery in pure DCIS. 
 
A) All recurrences  
Conventional clinicopathological parameters associated with high risk DCIS   
Parameters   Hazard ratio 
(HR) 
95% confidence interval (CI)   
p-value 
Lower Upper 
Patient Age 0.4 0.2 0.8 0.006 
DCIS presentation* 1.5 0.9 2.4 0.111 
DCIS size 1.5 1.1 2.1 0.040 
DCIS nuclear Grade 1.9 1.3 2.7 0.001 
Comedo necrosis 0.6 0.4 0.9 0.049 
Margin status  0.8 0.7 0.9 0.004 
TILs density and other clinicopathological parameters  
Patient Age 0.4 0.1 0.8 0.023 
DCIS presentation  1.5 0.9 3.8 0.395 
DCIS size 0.8 0.4 1.6 0.498 
DCIS nuclear Grade 1.2 0.6 2.4 0.662 
Comedo necrosis 0.6 0.3 1.3 0.196 
Margin status  0.9 0.9 1.1 0.637 
Overall TILs density  7.0 2.8 1.2 0.024 
Dense stromal FOXP3+ cells 1.7 0.7 0.3 0.453 
Dense stromal PDL1+ cells 6.8 3.1 1.4 0.004 
Overall TILs density with stromal FOXP3+ and stromal PDL1+ inflammatory cells  
Overall TILs density  3.5 1.5 8.2 0.003 
Dense stromal FOXP3+ cells 0.8 0.4 1.7 0.554 
Dense stromal PDL1+ cells 2.9 1.4 6.1 0.005 
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B) Invasive recurrence  
Conventional clinicopathological parameters associated with high risk DCIS   
Parameters   Hazard ratio 
(HR) 
95% confidence interval (CI)   
p-value 
Lower Upper 
Patient Age 0.5 0.2 1.3 0.156 
DCIS presentation  1.4 0.8 2.6 0.245 
DCIS size 1.8 1.1 2.4 0.013 
DCIS nuclear Grade 1.9 1.1 3.0 0.013 
Comedo necrosis 0.7 0.4 1.3 0.274 
Margin status  0.9 0.8 1.1 0.075 
TILs density and other clinicopathological parameters  
Patient Age 0.7 0.2 2.4 0.527 
DCIS presentation  2.2 0.6 7.5 0.206 
DCIS size 1.7 0.6 4.7 0.301 
DCIS nuclear Grade 2.6 0.8 8.2 0.111 
Comedo necrosis 0.7 0.2 2.0 0.497 
Margin status  0.9 0.9 1.1 0.877 
Overall TILs density  2.1 1.2 5.5 0.029 
Dense stromal FOXP3+ cells 0.3 0.1 1.4 0.143 
Dense stromal PDL1+ cells 1.7 0.6 5.1 0.307 
Overall TILs density with stromal FOXP3+ and stromal PDL1+ inflammatory cells  
Overall TILs density  2.8 1.1 7.9 0.045 
Dense stromal FOXP3+ cells 0.4 0.1 1.5 0.176 
Dense stromal PDL1+ cells 1.7 0.6 4.8 0.318 
Significant p values are in bold 
* DCIS presentation refers to the method of DCIS diagnosis either through the mammography screening program or 
symptomatic presentation.  
  
 
 
31 
 
Figure1 
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Figure 2 
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Figure 3 
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Figure 4 
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Supplementary Table 1: Clinicopathological characteristics of the study cohort  
 
Parameters 
Whole Pure 
DCIS cohort 
(n= 780) 
(n/%) 
Pure DCIS cohort 
included in this 
study* 
(n=413) 
(n/%) 
Whole 
DCIS/IBC 
cohort** 
(n=239) 
(n/%) 
DCIS/IBC 
cohort included 
in this study 
(n=154) 
(n/%) 
Age 
   ≤50 years 
   >50 years 
 
172 (22) 
608 (78) 
 
113 (27) 
300 (73) 
 
108 (45) 
131 (55) 
 
73 (47) 
81 (53) 
Presentation  
   Screening 
   Symptomatic  
 
430 (55) 
350 (45) 
 
186 (45)  
227 (55) 
 
NA 
 
 
NA 
 
DCIS Size 
   ≤20mm 
   >20mm 
 
392 (51) 
381 (49) 
 
168 (41) 
245 (59) 
 
88 (35) 
155 (65) 
 
53 (34) 
101 (66) 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
104 (13) 
194 (25) 
482 (62) 
 
54 (13) 
107 (26) 
252 (61) 
 
12 (5) 
60 (25) 
167 (70) 
 
8 (5) 
38 (25) 
108 (70) 
Comedo necrosis***  
   Yes 
   No 
 
497 (64) 
283 (36) 
 
273 (66) 
140 (34) 
 
175 (73) 
64 (27) 
 
111 (72) 
43 (28) 
Management  
   Breast conserving surgery 
   Mastectomy  
 
376 (48)  
404 (52) 
 
181 (44) 
232 (56) 
 
NA 
 
NA 
 
Estrogen receptor   
   Negative 
   Positive 
 
148 (25) 
439 (75) 
 
102 (21) 
260 (79) 
 
NA 
 
NA 
 
Progesterone receptor 
   Negative 
   Positive 
 
248 (42) 
336 (58) 
 
166 (45) 
200 (55) 
 
NA 
 
NA 
 
HER2 status  
   Negative 
   Positive 
 
516 (80) 
130 (20) 
 
288 (75) 
96 (25) 
 
NA 
 
NA 
 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple Negative  
 
248 (52) 
88 (19) 
64 (14) 
73 (15) 
 
159 (49) 
66 (20) 
53 (16) 
47 (15) 
 
 
NA 
 
NA 
 
*Refers to the number of cases included in the TMA used in this study as the number differs from the original cohort. The actual number of cases 
with informative TMA cores included in each study varies due to loss of some cores during sectioning and tissue processing prior to staining and was 
reduced with more markers stained. 
**DCIS component in the mixed cases 
***Comedo necrosis was defined as presence of central acellular necrosis with nuclear debris that can be seen using low power examination. Tiny / 
punctate necrosis or focal apoptosis was not considered as comedo necrosis. 
NA: No data available for the DCIS component in these cases, as the molecular classification and treatment were related to the invasive component 
not the DCIS component  
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Supplementary Table 2: Different antibodies used and their staining protocols 
Antibody Clone Source Species  Antigen retrieval Dilution Incubation Time 
CD3 SP7 Abcam Rabbit monoclonal Microwave in citrate PH6 1:300 24h 
CD8 C8/144B Dako Mouse monoclonal Microwave in citrate PH6 1:300 60min 
FOXP3 236A/E7 Abcam Mouse monoclonal Microwave in citrate PH6 1:300 24h 
CD20 L26 Dako Mouse monoclonal Microwave in citrate PH6 1:300 30min 
CD4 EPR6855 Abcam Rabbit monoclonal Microwave in citrate PH6 1:500 24h 
PD1 EH33 Cell signalling Mouse monoclonal Microwave in citrate PH6 1:75 24h 
PDL1 E1L3N Cell signalling Rabbit monoclonal EDTA PH9, water bath heating at 100c 1:25 24h 
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Supplementary Table 3: Distribution of various TILs in the pure DCIS cohort 
 sCD20 iCD20 sCD3 iCD3 sCD8 iCD8 sCD4 iCD4 sFOXP3 iFOXP3 sPD1 iPD1 sPDL1 tPDL1 
 Median 0 0 3 1 0 0 0 0 0 0 0 0 0 0 
 Minimum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 Maximum 60 40 100 50 30 20 60 25 25 10 40 15 35 100 
% Pure DCIS with high 
expression  
35 26 46 50 41 37 44 41 20 16 39 14 31 2 
     Numbers represent average number of cells / duct except PDL1 in the tumour which represent the percentage of positive 
cells. s; stromal, i; intratumoural and t; tumour epithelial cells  
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Supplementary Table 4 (a-d): Correlation between immune cell markers, immune checkpoints with the clinicopathological parameters in pure DCIS cohort 
a) 
Parameters 
Stromal CD20 +ve cells  
χ2 
(p-value) 
Intratumour CD20 +ve cells  
χ2 
(p-value) 
Stromal CD3 +ve cells 
χ2 
(p-value) 
Intratumour CD3 +ve cells 
χ2 
(p-value) 
Low  
(N=268) 
 
N. (%) 
High 
(n=145) 
 
N. (%) 
Low  
(N=305) 
 
N. (%) 
High 
(n=108) 
 
N. (%) 
Low 
(N=207) 
 
N. (%) 
High 
(n=203) 
 
N. (%) 
Low 
(N=207) 
 
N. (%) 
High 
(n=203) 
 
N. (%) 
Age 
   ≤50 years 
   >50 years 
 
66 (25) 
202 (75) 
 
47 (32) 
98 (68) 
 
2.9 
(0.090) 
 
79 (26) 
226 (74) 
 
34 (31) 
74 (69) 
 
1.2 
(0.264) 
 
55 (25) 
165 (75) 
 
56 (30) 
134 (70) 
 
1.1 
(0.309) 
 
52 (25) 
155 (75) 
 
59 (29) 
144 (71) 
0.8 
(0.369) 
Presentation  
   Screening 
   Symptomatic  
 
126 (47) 
142 (53) 
 
60 (41) 
85 (59) 
1.2 
(0.272) 
 
138 (45) 
167 (55) 
 
48 (44) 
60 (56) 
 
0.021 
(0.886) 
 
101 (50) 
119 (50) 
 
84 (44) 
106 (56) 
 
0.1 
(0.730) 
 
92 (44) 
115 (56) 
 
93 (46) 
110 (54) 
 
0.1 
(0.781) 
DCIS Size 
   ≤20mm 
   >20mm 
 
109 (41) 
158 (59) 
 
59 (41) 
85 (59) 
 
0.1 
(0.977) 
 
116 (38) 
187 (62) 
 
52 (48) 
56 (52) 
3.2 
(0.073) 
 
92 (42) 
128 (58) 
 
75 (40) 
113 (60) 
 
0.2 
(0.694) 
 
74 (36) 
132 (64) 
 
93 (46) 
109 (54) 
 
4.3 
(0.038) 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
43 (15) 
81 (28) 
168 (57) 
 
9 (6) 
27 (19) 
85 (75) 
 
19.1 
(<0.0001) 
 
36 (12) 
81 (27) 
188 (61) 
 
16 (15) 
27 (25) 
65 (60) 
 
0.676 
(0.713) 
 
 
41 (18) 
71 (33) 
108 (49) 
 
10 (5) 
35 (18) 
145 (77) 
 
34.5 
(<0.0001) 
 
26 (13) 
57 (28) 
124 (59) 
 
25 (12) 
49 (24) 
129 (64) 
0.7 
(0.711) 
Comedo necrosis  
   Yes 
   No 
 
163 (61) 
105 (39) 
 
110 (76) 
35 (24) 
9.5 
(0.002) 
 
207 (68) 
98 (32) 
 
66 (61) 
42 (39) 
1.6 
(0.202) 
 
132 (60) 
88 (40) 
 
139 (73) 
51 (27) 
 
7.9 
(0.005) 
 
140 (68) 
67 (32) 
 
131 (65) 
72 (35) 
 
0.4 
(0.507) 
Estrogen receptor   
   Negative 
   Positive 
 
45 (19) 
188 (81) 
 
57 (44) 
72 (56) 
 
25.4 
(<0.0001) 
 
83 (32) 
180 (68) 
 
19 (19) 
80 (81) 
 
5.4 
(0.020) 
 
28 (15) 
160 (85) 
 
73 (42) 
99 (58) 
 
33.8 
(<0.0001) 
 
53 (30) 
124 (70) 
 
48 (26) 
135 (74) 
0.6 
(0.433) 
Progesterone receptor 
   Negative 
   Positive 
 
87 (37) 
151 (63) 
 
79 (62) 
49 (38) 
 
21.3 
(<0.0001) 
 
132 (49) 
135 (51) 
 
34 (34) 
65 (66) 
 
6.6 
(0.010) 
 
62 (32) 
131 (68) 
 
103 (61) 
67 (39) 
 
29.5 
(<0.0001) 
 
86 (48) 
94 (52) 
 
79 (43) 
104 (57) 
 
0.8 
(0.378) 
HER2 status *  
   Negative 
   Positive 
 
202 (80) 
49 (20) 
 
86 (65) 
47 (35) 
 
11.6 
(0.001) 
 
205 (73) 
76 (27) 
 
83 (81) 
20 (19) 
2.3 
(0.126) 
 
170 (83) 
34 (17) 
 
115 (65) 
62 (35) 
 
16.9 
(<0.0001) 
 
144 (75) 
49 (25) 
 
141 (75) 
47 (25) 
0.1 
(0.930) 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple Negative 
 
    119 (58) 
42 (20) 
22 (11) 
23 (11) 
 
40 (34) 
24 (20) 
31 (26) 
24 (20) 
24.1 
(<0.0001) 
 
106 (46) 
45 (19) 
43 (19) 
38 (16) 
 
53 (57) 
21 (23) 
10 (12) 
9 (10) 
6.6 
(0.086) 
 
101 (62) 
32 (20) 
14 (9) 
14 (9)  
 
57 (35) 
34 (21) 
39 (24) 
32 (20) 
31.1 
(<0.0001) 
 
71 (46) 
31 (20) 
27 (18) 
25 (16) 
 
87 (52) 
35 (21) 
26 (15) 
21 (12) 
1.5 
(0.674) 
HIF1a expression 
   Low  
   High  
 
207 (83) 
44 (17) 
 
90 (63) 
53 (37) 
 
18.7 
(<0.0001) 
 
207 (72) 
80 (28) 
 
90 (84) 
17 (16) 
6.3 
(0.014) 
 
171 (84) 
33 (16) 
 
126 (66) 
64 (34) 
 
16.8 
(<0.0001) 
 
144 (75) 
49 (25) 
 
151 (76) 
48 (24) 
0.1 
(0.771) 
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b) 
Parameters 
Stromal CD4 +ve cells  
χ2 
(p-value) 
Intratumour CD4 +ve cells 
χ2 
(p-value) 
Stromal CD8 +ve cells 
χ2 
(p-value) 
Intratumour CD8 +ve 
cells 
χ2 
(p-value) 
Low 
(N=225) 
 
N. (%) 
High 
(N=178) 
 
N. (%) 
Low 
(N=233) 
 
N. (%) 
High 
(N=170) 
 
N. (%) 
Low 
(N=238) 
 
N. (%) 
High 
(n=164) 
 
N. (%) 
Low 
(N=253) 
 
N. (%) 
High 
(n=149) 
 
N. (%) 
Age 
   ≤50 years 
   >50 years 
 
55 (24) 
170 (76) 
 
57 (32) 
121 (68) 
 
2.8 
(0.092) 
 
65 (28) 
168 (72) 
 
47 (28) 
123 (72) 
0.1 
(0.956) 
 
54 (23) 
184 (77) 
 
57 (35) 
107 (65) 
 
6.6 
(0.010) 
 
65 (26) 
188 (74) 
 
46 (31) 
103 (69) 
1.3 
(0.262) 
Presentation  
   Screening 
   Symptomatic  
 
106 (47) 
119 (53) 
 
75 (42) 
103 (58) 
0.9 
(0.363) 
 
103 (44) 
130 (56) 
 
78 (46) 
92 (54) 
 
0.1 
(0.738) 
 
114 (48) 
124 (52) 
 
66 (40) 
98 (60) 
2.3 
(0.129) 
 
107 (42) 
146 (58) 
 
73 (49) 
76 (51) 
 
1.7 
(0.192) 
DCIS Size 
   ≤20mm 
   >20mm 
 
88 (39) 
137 (61) 
 
75 (43) 
101 (57) 
 
0.6 
(0.424) 
 
83 (36) 
150 (64) 
 
80 (48) 
88 (52) 
 
5.8 
(0.016) 
 
94 (40) 
144 (60) 
 
67 (41) 
95 (59) 
 
0.1 
(0.773) 
 
92 (36) 
161 (64) 
 
69 (47) 
78 (53) 
 
4.3 
(0.038) 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
40 (18) 
75 (34) 
110 (48) 
 
11 (6) 
29 (16) 
138 (78) 
 
36.9 
(<0.0001) 
 
29 (12) 
63 (27) 
141 (61) 
 
22 (13) 
41 (24) 
107 (63) 
 
0.4 
(0.803) 
 
43 (19) 
71 (29) 
123 (52) 
 
7 (4) 
35 (21) 
123 (75) 
 
26.0 
(<0.0001) 
 
37 (15) 
72 (29) 
144 (56) 
 
13 (9) 
34 (23) 
102 (68) 
5.8 
(0.055) 
Comedo necrosis  
   Yes 
   No 
 
143 (63) 
82 (37) 
 
125 (70) 
53 (30) 
 
2.2 
(0.134) 
 
165 (71) 
68 (29) 
 
103 (61) 
67 (39) 
4.6 
(0.032) 
 
148 (63) 
90 (37) 
 
119 (73) 
45 (27) 
 
4.3 
(0.037) 
 
168 (66) 
85 (34) 
 
99 (66) 
50 (34) 
0.1 
(0.993) 
Estrogen receptor   
   Negative 
   Positive 
 
28 (14) 
168 (86) 
 
73 (46) 
86 (54) 
 
44.8 
(<0.0001) 
 
61 (31) 
138 (69) 
 
40 (26) 
116 (74) 
1.1 
(0.299) 
 
38 (19) 
173 (81) 
 
62 (43) 
82 (57) 
 
25.1 
(<0.0001) 
 
54 (25) 
165 (75) 
 
46 (34) 
90 (66) 
 
3.5 
(0.062) 
Progesterone receptor 
   Negative 
   Positive 
 
66 (33) 
132 (67) 
 
96 (60) 
64 (40) 
 
25.0 
(<0.0001) 
 
101 (49) 
106 (51) 
 
61 (40) 
90 (60) 
2.5 
(0.115) 
 
 
77 (36) 
139 (64) 
 
 
85 (59) 
59 (41) 
 
 
19.0 
(<0.0001) 
 
 
93 (41) 
132 (59) 
 
 
69 (51) 
66 (49) 
 
3.3 
(0.071) 
HER2 status *  
   Negative 
   Positive 
 
175 (83) 
36 (17) 
 
107 (65) 
58 (35) 
 
14.3 
(<0.0001) 
 
159 (73) 
60 (27) 
 
123 (78) 
34 (22) 
1.6 
(0.205) 
 
184 (82) 
40 (18) 
 
97 (64) 
54 (36) 
 
15.4 
(0.001) 
 
182 (77) 
54 (23) 
 
99 (71) 
40 (29) 
1.6 
(0.203) 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple Negative 
 
110 (65) 
33 (19) 
13 (8) 
15 (8) 
 
47 (31) 
32 (21) 
40 (27) 
31 (21) 
44.4 
(<0.0001) 
 
80 (45) 
38 (22) 
32 (18) 
27 (15) 
 
77 (53) 
27 (19) 
21 (15) 
19 (13) 
2.2 
(0.527) 
 
120 (63) 
31 (16) 
18 (10) 
21 (11) 
 
37 (28) 
34 (26) 
35 (27) 
24 (19) 
40.3 
(<0.0001) 
 
102 (54) 
35 (18) 
29 (15) 
24 (13) 
 
55 (42) 
30 (23) 
24 (19) 
21 (16) 
4.1 
(0.260) 
HIF1a expression 
   Low  
   High  
 
180 (85) 
33 (15) 
 
112 (64) 
63 (36) 
24.1 
(<0.0001) 
 
168 (76) 
53 (24) 
 
124 (74) 
43 (26) 
0.2 
(0.690) 
 
196 (85) 
32 (15) 
 
97 (61) 
62 (39) 
 
29.1 
(<0.0001) 
 
188 (78) 
52 (22) 
 
105 (71) 
42 (29) 
 
2.4 
(0.124) 
 
 
40 
 
 
c) 
Parameters 
Stromal FOXP3 +ve cells  
χ2 
(p-value) 
Intratumour FOXP3 +ve cells  
χ2 
(p-value) 
Low 
(N=327) 
 
N. (%) 
High 
(N=79) 
 
N. (%) 
Low 
(N=330) 
 
N. (%) 
High 
(N=66) 
 
N. (%) 
Age 
   ≤50 years 
   >50 years 
 
91 (28) 
236 (72) 
 
 20 (25) 
59 (75) 
 
0.2 
(0.681) 
 
91 (27) 
239 (73) 
 
20 (30) 
46 (70) 
0.3 
(0.593) 
Presentation  
   Screening 
   Symptomatic  
 
143 (44) 
180 (56) 
 
39 (49) 
40 (51) 
0.7 
(0.405) 
 
156 (46) 
180 (54) 
 
26 (39) 
40 (61) 
1.1 
(0.294) 
DCIS Size 
   ≤20mm 
   >20mm 
 
132 (41) 
191 (59) 
 
31 (40) 
46 (60) 
 
0.1 
(0.931) 
 
134 (40) 
201 (60) 
 
29 (45) 
36 (55) 
0.5 
(0.488) 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
48 (15) 
90 (28) 
185 (57) 
 
1 (1) 
13 (17) 
65 (82) 
 
19.9 
(<0.0001) 
 
47 (14) 
92 (27) 
197 (59) 
 
2 (3) 
11 (16) 
53 (81) 
12.1 
(0.002) 
Comedo necrosis  
   Yes 
   No 
 
204 (63) 
119 (37) 
 
64 (19) 
15 (81) 
 
9.4 
(0.002) 
 
218 (65) 
118 (35) 
 
50 (76) 
16 (24) 
2.9 
(0.087) 
Estrogen receptor   
   Negative 
   Positive 
 
67 (24) 
214 (76) 
 
34 (53) 
39 (47) 
 
15.1 
(<0.0001) 
 
78 (27) 
216 (73) 
 
23 (38) 
37 (62) 
3.4 
(0.049) 
Progesterone receptor 
   Negative 
   Positive 
 
114 (40) 
173 (60) 
 
49 (69) 
22 (31) 
 
19.8 
(<0.0001) 
 
127 (42) 
172 (53) 
 
36 (61) 
23 (39) 
6.8 
(0.009) 
HER2 status *  
   Negative 
   Positive 
 
240 (80) 
64 (20) 
 
40 (58) 
31 (42) 
 
13.7 
(<0.0001) 
 
244 (78) 
70 (22) 
 
36 (59) 
25 (41) 
9.4 
(0.002) 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple Negative  
 
140 (55) 
48 (20) 
31 (12) 
35 (13) 
 
17 (25) 
17 (25) 
22 (33) 
11 (17) 
24.6 
(<0.0001) 
 
139 (53) 
46 (17) 
39 (15) 
37 (15) 
 
17 (29) 
18 (31) 
14 (24) 
9 (16) 
12.3 
(0.006) 
HIF1a expression 
   Low  
   High  
 
251 (81) 
58 (19) 
 
39 (50) 
39 (50) 
32.7 
(<0.0001) 
 
256 (80) 
66 (20) 
 
34 (52) 
31 (48) 
21.3 
(<0.0001) 
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d) 
Parameters 
Stromal PD1 +ve cells  
χ2 
(p-value) 
Intratumour PD1 +ve cells 
χ2 
(p-value) 
Stromal PDL1 +ve cells 
χ2 
(p-value) 
Low  
(N=241) 
 
N. (%) 
High 
(n=152) 
 
N. (%) 
Low  
(N=338) 
 
N. (%) 
High 
(n=55) 
 
N. (%) 
Low  
(N=264) 
 
N. (%) 
High 
(n=119) 
 
N. (%) 
Age 
   ≤50 years 
   >50 years 
 
63 (26) 
178 (74) 
 
47 (31) 
105 (69) 
 
0.9 
(0.328) 
 
95 (28) 
243 (72) 
 
15 (27) 
40 (73) 
0.1 
(0.898) 
 
65 (25) 
199 (75) 
 
40 (34) 
79 (66) 
 
3.3 
(0.068) 
Presentation  
   Screening 
   Symptomatic  
 
114 (47) 
127 (53) 
 
64 (42) 
88 (58) 
0.8 
(0.357) 
 
154 (46) 
184 (54) 
 
24 (44) 
31 (56) 
0.1 
(0.790) 
 
128 (49) 
136 (51) 
 
45 (38) 
74 (62) 
 
3.8 
(0.052) 
DCIS Size 
   ≤20mm 
   >20mm 
 
97 (41) 
144 (59) 
 
59 (39) 
91 (61) 
 
0.6 
(0.806) 
 
132 (39) 
206 (61) 
 
24 (45) 
29 (55) 
0.742 
(0.389) 
 
114 (43) 
150 (57) 
 
39 (33) 
79 (67) 
 
3.8 
(0.062) 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
40 (17) 
83 (35) 
118 (48) 
 
9 (6) 
22 (15) 
121 (79) 
 
37.7 
(<0.0001) 
 
48 (14) 
95 (28) 
195 (58) 
 
1 (2) 
10 (18) 
44 (80) 
11.4 
(0.003) 
 
42 (16) 
79 (30) 
143 (54) 
 
7 (6) 
22 (19) 
90 (75) 
 
16.7 
(<0.0001) 
Comedo necrosis  
   Yes 
   No 
 
146 (60) 
95 (40) 
 
117 (77) 
35 (23) 
11.7 
(0.001) 
 
223 (66) 
115 (34) 
 
40 (73) 
15 (27) 
0.9 
(0.324) 
 
169 (64) 
95 (36) 
 
86 (72) 
33 (28) 
 
2.5 
(0.113) 
Estrogen receptor   
   Negative 
   Positive 
 
32 (15) 
176 (85) 
 
66 (46) 
76 (54) 
 
41.6 
(<0.0001) 
 
76 (25) 
222 (75) 
 
22 (42) 
30 (58) 
6.2 
(0.013) 
 
46 (20) 
187 (80) 
 
53 (49) 
55 (51) 
 
30.8 
(<0.0001) 
Progesterone receptor 
   Negative 
   Positive 
 
 
66 (30) 
149 (70) 
 
 
95 (67) 
46 (33) 
 
 
47.8 
(<0.0001) 
 
 
125 (41) 
180 (59) 
 
 
36 (71) 
15 (29) 
 
15.5 
(<0.0001) 
 
 
 
82 (35) 
152 (65) 
 
 
74 (68) 
35 (32) 
 
 
32.4 
(<0.0001) 
HER2 status *  
   Negative 
   Positive 
 
187 (84) 
37 (16) 
 
85 (60) 
57 (40) 
 
12.9 
(<0.0001) 
 
243 (77) 
71 (23) 
 
29 (56) 
23 (44) 
10.9 
(0.001) 
 
199 (82) 
44 (18) 
 
64 (58) 
47 (42) 
 
23.4 
(<0.0001) 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple Negative 
 
117 (64) 
34 (19) 
14 (7) 
18 (10) 
 
39 (29) 
30 (23) 
40 (30) 
24 (18) 
47.4 
(<0.0001) 
 
137 (51) 
55 (21) 
39 (15) 
35 (13) 
 
19 (38) 
9 (18) 
15 (30) 
7 (14) 
7.5 
(0.057) 
 
123 (60) 
37 (18) 
23 (11) 
21 (11) 
 
25 (25) 
25 (25) 
30 (29) 
22 (21) 
38.4 
(<0.0001) 
HIF1a expression 
   Low  
   High  
 
191 (85) 
34 (15) 
 
91 (61) 
59 (39) 
28.1 
(<0.0001) 
 
251 (78) 
70 (22) 
 
31 (57) 
23 (43) 
10.7 
(0.001) 
 
208 (85) 
37 (15) 
 
65 (55) 
53 (45) 
 
37.9 
(<0.0001) 
Significant p values are in bold. 
DCIS; ductal carcinoma in situ, HER2; Human epidermal growth factor receptor 2, HIF1A; hypoxia inducible factor 1 alpha. 
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Supplementary Figures  
 
Supplementary Figure 1: Low power view (4x), showing distribution of CD20, CD3, 
CD4 and CD8 in a DCIS case. It is noticed that CD20 and CD3 are the most predominant 
subtypes. Also, CD4+ cells are more predominant T lymphocytes’ subtype than CD8+ 
cells.   
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Supplementary Figure 2: Bar charts showing the difference between expression of 
various immune cells and checkpoint proteins in pure DCIS and DCIS coexisting with 
invasive disease; a) stromal CD20+, b) stromal CD3+, c) stromal CD8+, d) stromal CD4+, 
e) stromal FOXP3+, f) stromal PD1+, g) stromal PDL1+, h) intratumoural CD20+, i) 
intratumoural CD3+, j) intratumoural CD8+, k) intratumoural CD4+, l) intratumoural 
FOXP3+ and m) intratumoural PD1+ lymphocytes.  Error bars represent +2 standard 
deviation.  
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Supplementary Figure 3: Violin plots showing the association between various 
clinicopathological parameters, TP53 mutation with (A-E) the fraction of genomic altered (FGA) and 
with (F-I) number of telomeric allelic imbalances (NTAI). The central red dots represent the 
mean, boxes represent the interquartile range, central line represent the median and 
whiskers shows the 95% confidence interval. 
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Supplementary Figure 4: Kaplan Meier Curves showing; A) Higher TILs density is 
associated with shorter local recurrence free interval in high risk DCIS defined as high 
grade DCIS with size>1.5cm. B) High stromal PDL1 expression is associated with shorter 
local recurrence free interval (LRFI) in high risk DCIS. 
 
 
